<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605305</url>
  </required_header>
  <id_info>
    <org_study_id>FOLFOX6-2008</org_study_id>
    <nct_id>NCT01605305</nct_id>
  </id_info>
  <brief_title>Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer</brief_title>
  <official_title>Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore whether FOLFOX6 as treatment could improve the time to
      progression (TTP) and overall survival (OS) of the patient with recurrent or metastatic
      esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore whether FOLFOX6 as treatment could improve the TTP and OS of the patient with
      recurrent or metastatic esophagus
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TPP</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6</intervention_name>
    <description>OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h</description>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven primary thoracic esophageal squamous cell carcinoma

          2. Without chemotherapy or neo-adjuvant chemotherapy in 6 weeks ,radiotherapy has end at
             least 1 month,target lesion was not in an irradiated area.

          3. Presence of at least one index lesion measurable by CT scan or MRI

          4. 18~75 years

          5. kps ≥ 70

          6. Life expectancy of ≥ 3 months

          7. ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L

          8. Cr ≤ 1.0×UNL

          9. TB ≤ 1.25×UNL； ALT/AST ≤ 2.5×UNL，THE patient with liver metastasis ALT/AST ≤
             5.0×UNL；AKP ≤ 2.5×UNL

         10. Signed written informed consent

        Exclusion Criteria:

          1. Previous exposure to oxa therapy in one year

          2. diameter of tumor abdominal ≥ 10cm, Total volumes of liver lesions ≥ 50%,lung
             metastasis ≥ 25% total lung

          3. chronic diarrhea,enteritis,intestine obstruction which are not under control

          4. Psychiatric or addictive disorders that preclude obtaining informed consent or
             adherence to protocol.

          5. peripheral neuropathy ≥ CTCAE 1

          6. Other serious disease

          7. Previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in
             situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or
             endometrium treated five years prior to study entry.

          8. USE OTHER ANTITUMOR THERAPY

          9. Breast-feeding or pregnant women, no effective contraception if risk of conception
             exists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chang j h, post-doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

